High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
Authors:
Open Access
- 13 April 2021
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 12 (8) , 859-872
Abstract
Https://doi.org/10.18632/oncotarget.27930 Elodie Montaudon, Rania El Botty, Sophie Vacher, Olivier Déas, Adnan Naguez, Sophie Chateau-Joubert, Damien Treguer, Ludmilla de Plater, Leïla Zemoura,...Keywords
This publication has 42 references indexed in Scilit:
- Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancerCancer, 2010
- High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancerBritish Journal of Cancer, 2010
- PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell linesCancer Letters, 2009
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsAnnals of Oncology, 2009
- The Potential Role of mTOR Inhibitors in Non-Small Cell Lung CancerThe Oncologist, 2008
- Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancerCancer, 2007